Kira Biotech

About:

Kira Biotech is an Immunology Company.

Top Investors: IP Group, OneVentures, Queensland Business Development Fund

Description:

Kira Biotech is an emerging Australian biotechnology company developing novel immunomodulatory compounds for the treatment of immune system disorders. Its lead candidate, KB312, is a first-in-class, selective, immune-cell depleting monoclonal antibody which targets activated immune cells and aims to restore homeostasis through induction of immune tolerance. Kira Biotech has attracted venture capital funding and is progressing KB312 through preclinical development and phase 1 clinical trials with a team of drug development experts led by well-known US-based rheumatologist and immunologist, Dr Dan Baker.

Total Funding Amount:

20M AUD

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Brunswick, Maine, United States

Founded Date:

2019-01-01

Contact Email:

enquiries(AT)kirabiotech.com

Founders:

Dan Baker, Helen Roberts

Number of Employees:

1-10

Last Funding Date:

2019-10-28

IPO Status:

Private

Industries: